NCT07683585Recruiting
Comparative Effectiveness of Dual Antihypertensive Regimens in Patients After Percutaneous Coronary Intervention
Source: ClinicalTrials.gov · Last updated 6 Jul 2026
Brief summary (registry, in English)
This prospective randomized open-label study aims to compare the effectiveness of two dual antihypertensive therapy regimens in patients with arterial hypertension and coronary artery disease after elective percutaneous coronary intervention (PCI) with coronary artery stenting. Patients requiring dual antihypertensive therapy will be randomized to receive either an angiotensin receptor blocker (ARB) combined with a thiazide diuretic or an ARB combined with a dihydropyridine calcium channel blocker. The study will evaluate blood pressure control, angina symptoms, quality of life, need for treatment intensification, and healthcare utilization during follow-up. Clinical status will be assessed at discharge and during telemedicine follow-up visits at 2 weeks, 4 weeks, and 12 weeks after hospital discharge. The primary endpoint is the percentage reduction in systolic and diastolic blood pressure. Secondary endpoints include frequency of angina episodes, exercise limitations, patient satisfaction with treatment, and medical consultations during follow-up. The study is investigator-initiated and plans to enroll at least 207 participants.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 207 (estimated)
- First submitted
- 18 May 2026
- Start date
- Apr 2026
- Primary completion date
- Jul 2026
- Lead sponsor
- National Medical Research Center for Therapy and Preventive Medicine
- Diseases
- High blood pressure
- NCT number
- NCT07683585
What you commit to
- Study type: Interventional
- Planned participants: 207
- From Apr 2026 to the primary completion date, Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications or intolerance to study medications, including bilateral renal artery stenosis, hyperkalemia, hyperuricemia, or gout
Other illness
- Acute coronary syndrome
- Active malignancy
- Chronic kidney disease stage 4-5
- Type 2 diabetes mellitus
- Any other condition that, in the investigator's opinion, may interfere with participation in the study or interpretation of study results
Lab values
- Heart failure with reduced ejection fraction
Age
- Women of reproductive age
Other
- Refusal or inability to provide informed consent
- Pulmonary embolism
- Permanent or persistent atrial fibrillation
- Planned staged coronary stenting
Who the study is looking for
- Age 50 to 70 years
- Arterial hypertension
- Coronary artery disease
- Hospitalization for elective percutaneous coronary intervention
- Coronary artery stenting during the current hospitalization
- Requirement for dual antihypertensive therapy
- Treatment with beta-blockers, lipid-lowering therapy, and antiplatelet therapy
- Ability and willingness to provide written informed consent
Age in the registry: 50 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Medical Research Center for Therapy and Preventive Medicine Coordinator of this site? Confirm its status | Moscow | Russia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.